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Composite monolithic adsorbents were prepared by the incorporation of neutral polystyrene divinylbenzene (PS-DVB)
microparticles into macroporous polymer structures produced by cryogelation of agarose or poly(vinyl alcohol). The composite
materials exhibited excellent flow-through properties. Scanning electron microscopy of the composite cryogels revealed that the
microparticles were covered by thin films of poly(vinyl alcohol) or agarose and thus were withheld in the monolith structure.
Plain PS-DVB microparticles showed efficient adsorption of albumin-bound toxins related to liver failure (bilirubin and cholic
acid) and of cytokines (tumor necrosis factor-alpha and interleukin-6). The rates of adsorption and the amount of adsorbed
factors were lower for the embedded microparticles as compared to the parent PS-DVB microparticles, indicating the importance
of the accessibility of the adsorbent pores. Still, the macroporous composite materials showed efficient adsorption of albumin-
bound toxins related to liver failure as well as efficient binding of cytokines, combined with good blood compatibility. Thus, the
incorporation of microparticles into macroporous polymer structures may provide an option for the development of adsorption
modules for extracorporeal blood purification.
1. Introduction
Monolithic cryogels are produced in a semi-frozen aqueous
state by radical polymerization of water-soluble monomers
or by cross-linking of water-soluble polymers [1–3]. Ice
crystals grow during freezing and finally occupy about 90%
of the volume, while the chemical reactions take place in
a highly concentrated unfrozen liquid microphase. After
defrosting, voids appear as a result of ice melting and form an
interconnectedmacroporous polymer structure (MPPS)with
pore diameters up to 200 to 300 𝜇m, whereas the pore walls
are represented by thin and dense sheets of the cross-linked
polymer. Cryogel monoliths are typically elastic, spongy, and
highly permeable for aqueous media. Various applications of
cryogels in biotechnology and biomedical sciences have been
reported [1, 4–7]. In particular, cryogels and hydrogels based
on poly(vinyl alcohol) and agarose are low-cost, nontoxic,
and biocompatible polymers and have been employed for
the production of biomaterials and cell culture scaffolds [8–
13]. Both PVA- and agarose-based cryogels are characterized
by supermacroporous morphology, but differences in their
overall properties exist. Cryogels made of agarose are rigid
and brittle, whereas PVA-based cryogels possess a high
degree of elasticity and toughness. A series of reactive and
functional cryogels was developed [3–5], including cryogels
capable of removing toxins from protein solutions [14, 15].
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Here, we report on the application of PVA- and agarose-based
MPPS to remove toxic metabolites related to liver failure and
cytokines from blood plasma.
Liver failure is associated with a diminished detoxifica-
tion capability of the liver, resulting in the accumulation
of hydrophobic toxic metabolites in the blood. Metabo-
lites such as bile acids, bilirubin, tryptophan, and phenolic
compounds are albumin-bound, and thus, they cannot be
removed by diffusive or convective extracorporeal blood
purification systems, but require adsorptive techniques for
depletion [16, 17]. Extracorporeal liver support systems apply
columns containing polystyrene divinylbenzene (PS-DVB)
copolymers to remove toxic metabolites via hydrophobic
interactions [18–20]. In particular, neutral PS-DVB copoly-
mers of adequate porosity (8-9 nm pore diameter) are effi-
cient adsorbents for albumin-bound toxicmetabolites [21]. In
addition to extracorporeal blood purification, the depletion
of toxic metabolites from human plasma is also relevant for
research purposes. This was demonstrated by in vitro studies
investigating the effect of the removal of toxic metabolites
related to liver failure from plasma on cultured hepatocytes
[22]. These and similar research applications require simple
adsorbent devices with low resistance to the flow of plasma in
combination with the fast adsorption of toxins.The latter can
be achieved by using small adsorbent particles, providing a
large outer surface area. However, the dense packing of small
particles supported by filters of adequate porosity creates
significant flow resistance. Therefore, a promising approach
to the design of effective adsorbentsmay be the incorporation
of PS-DVB copolymer microparticles into highly permeable
monolithic MPPS, which are well compatible with common
low-pressure chromatography columns or syringes.
The aim of this study was to producemonolithic compos-
ite cryogels based on poly (vinyl alcohol) and agarose with
embedded PS-DVB microparticles and to characterize them
with respect to flow through, adsorption,mechanical stability
and biocompatibility. Since the pore size distribution and
the accessibility of the pores is critical for the adsorption
characteristics of PS-DVB microparticles, we assessed the
influence of the embedding procedure on the accessibility of
the adsorbent pores by comparing plain PS-DVB particles
and PS-DVB particles embedded into monolithicMPPS with
respect to their adsorption characteristics for cytokines and
hydrophobic metabolites related to liver failure.
2. Materials and Methods
2.1. Materials. Fresh frozen human plasma was obtained
from a local plasma donation center (Retz, Austria). To
remove cryoprecipitates, the plasma was centrifuged at
3,600 g for 10min at room temperature after thawing.
Alternatively, blood was drawn from healthy volunteers
into tubes containing trisodium citrate (Greiner Bio-One,
Kremsmu¨nster, Austria) after informed consent of the
donors. To obtain plasma, the blood was centrifuged for
10min at 3,600 gwithout brake. Bilirubin, cholic acid, phenol,
tryptophan, glutaraldehyde, and sodium cyanoborohydride
were purchased from Sigma-Aldrich (Steinheim, Germany).
All other chemicals were obtained from Merck (Darmstadt,
Germany). Poly(vinyl alcohol) (PVA, Mowiol 18–88) was
purchased fromClariant (Frankfurt amMain, Germany) and
agarose was obtained from Fluka Chemie (Buchs, Switzer-
land).
2.2. Polystyrene Divinylbenzene Copolymers. Polystyrene
divinylbenzene copolymer microparticles were provided by
Polymerics GmbH, Berlin, Germany [23]. The average pore
size of the microparticles was 7.7 nm and the BET surface
was 680m2 per g. The total pore volume of the particles was
1.37mL/g, with a micropore volume (pores below 2 nm)
of 0.27mL/g, a mesopore volume (pores between 2 and
50 nm) of 0.88mL/g, and a macropore volume (pores above
50 nm) of 0.22mL/g. Prior to use, the adsorbent particles
were washed in ethanol, distilled water, and 0.9% (w/v)
saline solution, followed by centrifugation at 3,500 g for
5min after each washing step. The size distribution was
determined using a Mastersizer 2000 (Malvern Instruments
Ltd., Malvern, UK). The average particle size was 85.5 𝜇m.
2.3. Preparation of Cryogels. Monolithic cryogels used in this
study are available from Protista (Bjuv, Sweden) under the
trademark of MPPS (macroporous polymeric structures).
Synthesis of the monolithic MPPS cryogels was carried
out using a liquid bath cryostat (Proline RP 1840, Lauda-
Koenigshofen, Germany) and an air bath cryostat (Arctest
Oy, Espoo, Finland). All gels were prepared in 2mL syringes
in order to obtain monoliths with a diameter of 9mm and a
length of 20mm.
For the preparation of PVA cryogels, 4.5% (w/v) PVA
solution in 0.1MHCl was put into an ice bath and kept at
4∘C for 30min. Glutaraldehyde (50%, w/v) was added to
the cooled solution at a final concentration of 1% (w/v) and
the mixture was precooled for 60min in the liquid bath
cryostat at −12∘C and subsequently transferred to the air bath
cryostat where the samples were kept at −12∘C, overnight.
To prepare PVA-based composite cryogels, 125mg PS-DVB
microparticles (dry weight) were washed twice with 5% (w/v)
PVA and once with 4.5% (w/v) PVA in 0.1MHCl, followed
by centrifugation at 6,700 g for 4min after each washing step.
The microparticles were resuspended in acidic 4.5% PVA
solution to a final volume of 1.2mL and the cryogels were
produced as described above. After defrosting, the cryogels
were washed with distilled water and the residual aldehyde
groups were reduced by circulating 0.1MNaBH
3
CN solution
in 0.1M sodium bicarbonate buffer (pH 9.2) through the
cryogels at a flow rate of 0.5mL/min at 4∘C for 4 h.Thereafter,
the cryogels were extensively washed with distilled water.
To preparemonolithic agarose-based composite cryogels,
agarose was dissolved at 3% (w/v) in boiling deionized water
and the pHwas adjusted to 12.5–13.0 withNaOH.The agarose
solution was added to 125mg PS-DVBmicroparticles, mixed
and centrifuged at 14,100 g for 30–60 sec. The particles were
resuspended in the agarose solution to a final volume of
1.2mL and the suspensionwas transferred into 2mL syringes.
The cryogels were immediately placed into the liquid bath
cryostat (−32∘C, 30min) and thereafter into the air bath
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cryostat (−12∘C, overnight). To prepare agarose cryogels, the
above procedure was performed without the addition of
microparticles. After defrosting, the cryogelswere extensively
washed with distilled water and stored in 20% (v/v) ethanol
at 4∘C.
2.4. Scanning Electron Microscopy. Discs of 4mm thickness
were cut from the top and bottom of the cryogels and fixed
overnight in 2.5% (v/v) glutaraldehyde in 0.12M sodium
phosphate buffer (pH 7.2). Samples were dehydrated with
increasing concentrations of ethanol (30, 50, 75, and 99.5%
v/v), critical point dried (CPD 030 critical point dryer, BAL-
TEC AG, Balzers, Liechtenstein), and coated with gold-
palladium (40 : 60) using a Polaron SC7640 High Resolution
Sputter Coater (Thermo VG Microtech, West Sussex, Great
Britain). The samples were examined on a JEOL JSM-5600
LV scanning electron microscope at an acceleration voltage
of 7 kV. The pore sizes of the cryogels were estimated based
on these images.
2.5. Flow Characteristics of the Cryogels. The flow rate of
water through particle-free and composite cryogels was
assessed at different pressures. The hydrostatic pressure was
adjusted to 1, 4, 8, and 15 kPa and the time and volume
of water flowing through the monoliths were recorded to
calculate the flow rate in mL/min.
2.6. Particle Leakage. Particle-free cryogels and composite
cryogels were washed with 4-5 column volumes of deionized
water. Subsequently, 25mL of deionized water was passed
through plain cryogels and composite cryogels at a flow
rate of 1mL/min. The quantity of particles released from
the cryogels was determined in the flow through by light
obscuration using a HIAC Royco device (Pacific Scientific
Instruments, Oregon, USA).
2.7. Adsorption of Toxins Related to Liver Failure. Human
plasma was spiked with 300𝜇M bilirubin, 100 𝜇M cholic
acid, 100𝜇M tryptophan, and 2mM phenol. Adsorption of
bilirubin and cholic acid to the cryogels was assessed under
static and dynamic conditions. For the static setup, plain
cryogels and composite cryogels were cut into 4mm slices,
which were incubated with 7.65mL of spiked plasma at 37∘C
with gentle shaking. For comparison, the equivalent amount
of plain PS-DVBmicroparticles (125mg) was incubated with
spiked plasma. For the dynamic setup, 13mL of spiked plasma
was recirculated through the plain and composite cryogels
at a flow rate of 1mL/min. For both setups, samples were
taken after 0, 15, 30, 60, and 120min. After immediate
centrifugation (18,600 g, 3min), the supernatants were stored
at −20∘C until further analysis. Bilirubin, cholic acid, and
albumin were quantified using a Hitachi 902 analyzer (Roche
Diagnostics, Mannheim, Germany).
2.8. Adsorption of Cytokines. Recombinant human tumor
necrosis factor-alpha (TNF-𝛼) and interleukin-6 (IL-6) were
purchased from R&D Systems, Minneapolis, USA. Human
plasma was spiked with TNF-𝛼 and IL-6 at target concentra-
tions of 500 pg/mL and 200 pg/mL, respectively. Particle-free
cryogels and composite cryogels containing 125mg PS-DVB
microparticles were cut into slices (4mm) and incubated
at a 10% (v/v) microparticle-to-plasma-ratio at 37∘C with
gentle shaking. Samples were taken after 0, 15, and 60min.
For comparison, the equivalent amount of plain PS-DVB
microparticles (125mg) was incubated with spiked plasma as
described above. Cytokines were quantified by ELISA (R&D
Systems Quantikine, Minneapolis, USA).
2.9. Activation of Coagulation. The blood compatibility of
PS-DVB microparticles, particle-free cryogels, and compos-
ite cryogels was assessed using two global coagulation tests,
namely, prothrombin time (PT), which detects coagulation
deficiencies in the extrinsic coagulation pathway, and acti-
vated partial thromboplastin time (aPTT), which detects
coagulation deficiencies in the intrinsic coagulation pathway.
Single 4mm slices of the composite cryogels were incubated
with plasma at a 10% (v/v) microparticle-to-plasma-ratio for
60min at 37∘C. Equivalent volumes of plain PS-DVBparticles
served as controls. Thereafter, the samples were centrifuged
for 3min at 18,600 g. PT and aPTTwere determined from the
supernatants using a Sysmex CA-500 coagulation analyzer
(Sysmex Corporation, Kobe, Japan) and the reagents Dade
Innovin and Dade Actin FS (both from Siemens Healthcare
Diagnostic Products GmbH, Marburg, Germany) according
to the instructions of the manufacturers.
3. Results and Discussion
3.1. Characterization of Plain Cryogels. Scanning electron
microscopy (SEM) revealed that the particle-free monolithic
PVA cryogels possessed randomly shaped pores (Figures
1(a) and 1(b)). The majority of the pores had a diameter
of 100–140 𝜇m. In addition, smaller pores with a diameter
of 10–60𝜇m were observed. Plain PVA cryogels had dense
pore walls consisting of thin polymerized layers of PVA
(Figure 1(b)). PVA cryogels yielded maximum flow rates of
3.6mL/min at 8 kPa. At higher pressures, the flow rates did
not increase due tomechanical compression of the gels, which
was associatedwith increasing resistance to the flow (Table 1).
In contrast to PVA-based cryogels, agarose-based cryo-
gels showed regular elongated pores with a length of several
hundred micrometers and a width of about 60–70𝜇m.
The monolithic agarose-based cryogels had very thin pore
walls, fromwhich small irregular protrusions were extending
(Figure 2(a)). The surface of the pore walls was smooth
and non-porous (Figure 2(b)). Agarose cryogels were less
permeable than PVA cryogels. The flow rate through agarose
cryogels reached a maximum of 2.9mL/min at 4 kPa and
decreased at a pressure of 15 kPa (Table 1).
3.2. Composite Cryogels. When developing composite cryo-
gels, we aimed to embed significant amounts of PS-DVB
microparticles to achieve high adsorption capacities. Sus-
pending 125mg PS-DVB microparticles in 1.2mL of PVA
solution corresponded to an approximately twofold weight
4 Journal of Chemistry
(a) (b)
(c) (d)
Figure 1: Scanning electron micrographs of plain PVA cryogels (a)-(b) and PVA-based composite cryogels loaded with 125mg PS-DVB
microparticles (c)-(d).
Table 1: Flow characteristics of particle-free and composite cryogels (𝑛 ≥ 4).
Cryogel matrix PS-DVB Flow rate [mL/min]
1 kPa 4 kPa 8 kPa 15 kPa
PVA — 1.0 ± 0.8 3.2 ± 1.2 3.6 ± 2.4 3.2 ± 1.8
125mg 0.5 ± 0.7 1.5 ± 1.4 2.4 ± 0.6 4.2 ± 1.6
Agarose — 0.8 ± 0.2 2.9 ± 1.8 2.8 ± 1.8 1.8 ± 1.2
125mg 1.2 ± 0.7 4.0 ± 3.0 5.9 ± 4.8 6.7 ± 6.0
excess of PS-DVB microparticles over PVA. The pores
within the resulting composite cryogels were in the range
of 10–60𝜇m, and 40–60𝜇m pores were the most common
(Figure 1(c)). Thus, the pore size was reduced as compared
to particle-free PVA cryogels. Overall, the macroporous
structure of plain cryogels significantly differed from that
of composite cryogels, as embedded microparticles occupied
the cryogel macropores.
The flow rates for PVA-based composite cryogels
increased in a linear way with increasing pressure. The flow
rate for PVA-based composite cryogels loaded with 125mg
microparticles was 4.2mL/min at 15 kPa. For agarose-based
composite cryogels the pore sizes varied between 10 and
150𝜇m (Figure 2(c)). Agarose-based composite cryogels
showed improved mechanical stability in comparison to
particle-free cryogels, as they could be tested at a pressure
of 15 kPa, yielding flow rates of 6.7mL/min when loaded
with 125mg of microparticles. In conclusion, the mechanical
strength of both PVA- and agarose-based cryogels was
improved due to the integration of PS-DVB microparticles.
Therefore, the composite cryogels allowed the testing at
higher pressures and higher flow rates could be achieved as
compared to plain cryogels. In the case of PVA composite
cryogels, the PS-DVB microparticles were covered by PVA
layers and showed a stable integration into the cryogel
(Figures 1(c) and 1(d)). In contrast, the PS-DVB particles
embedded into agarose-based cryogels appeared to be less
tightly incorporated into the gel structure but were rather
mechanically entrapped inside the pores (Figure 2(c)).
3.3. Particle Leakage. None of the effluents collected from
the composite cryogels contained microparticles in the size
range of 40–100𝜇m. Thus, the composite cryogels did not
need filters to support the embedded microparticles, which
were withheld inside the macroporous polymer structure.
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Figure 2: Scanning electronmicrographs of plain agarose cryogels (a)-(b) and agarose-based composite cryogels loadedwith 125mg PS-DVB
microparticles (c)-(d).
Table 2: Adsorption of bilirubin under static and dynamic conditions after 15 and 60min (𝑛 = 3).
𝜇mol bilirubin adsorbed per g PS-DVB
Static Dynamic
15min 60min 15min 60min
PS-DVB 3.3 ± 0.2 4.3 ± 0.2 n.a.a n.a.a
PVA + 125mg PS-DVB 0.5 ± 0.4 1.3 ± 0.3 0.6 ± 0.2 2.1 ± 0.7
Agarose + 125mg PS-DVB 1.2 ± 0.4 2.8 ± 0.9 2.6 ± 1.9 5.0 ± 0.5
aNot applicable.
3.4. Adsorption of Toxins Related to Liver Failure. The
adsorption characteristics of parent PS-DVB microparticles
and PS-DVB microparticles embedded into cryogels were
investigated under static and dynamic conditions. Under
static conditions, the adsorption of bilirubin was reduced by
a factor of 3.3 and 1.5, respectively, for PS-DVB micropar-
ticles embedded into PVA- and agarose-based cryogels as
compared to the parent microparticles (Table 2). Likewise,
cholic acid adsorption was reduced by a factor of 4.5 and
3.4, respectively, for PS-DVB microparticles embedded into
PVA- and agarose-based cryogels as compared to the parent
PS-DVB microparticles (Table 3). Nevertheless, cholic acid
was reduced to 10% and 6.6% of the initial concentration
for PVA-based and agarose-based cryogels containing 125mg
microparticles, respectively.
The importance of convective mass transfer for the
adsorption of toxins was reflected by the results of dynamic
experiments where the adsorbed amounts of both, bilirubin,
Table 3: Adsorption of cholic acid under static and dynamic
conditions after 60min (𝑛 = 3).
Cholic acid adsorbed per
𝜇mol/g PS-DVB
Static Dynamic
PS-DVB 22.2 ± 0.4a n.a.b
PVA + 125mg PS-DVB 4.9 ± 0.2 9.6 ± 0.5
Agarose + 125mg PS-DVB 6.5 ± 0.3 9.4 ± 0.5
aCalculated based on an assay with 1% (v/v) adsorbent-to-plasma-ratio.
bNot applicable.
and cholic acid were generally higher than under static
conditions (Tables 2 and 3). Agarose-based composite cryo-
gels performed superiorly with respect to bilirubin removal
than PVA-based composite cryogels (5.0 ± 0.5 𝜇mol/g versus
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Figure 3: Prothrombin time (PT) and activated partial thromboplastin time (aPTT) for PVA- and agarose-based composite cryogels and
parent PS-DVB microparticles. The horizontal lines refer to the reference range of the respective coagulation parameter.
2.1 ± 0.7 𝜇mol/g, Table 2), while no difference was observed
with respect to cholic acid removal.
The finding that the accessibility of the pores had a greater
influence on the adsorption of bilirubin as compared to cholic
acid may be explained by the different affinities of cholic
acid and bilirubin for albumin: bilirubin is strongly albumin-
bound with an association constant of 9.5 × 107M−1, corre-
sponding to an unbound fraction at the equilibrium of less
than 0.1% [24], while the association constant of cholic acid is
0.3 × 104M−1, corresponding to a free fraction of cholic acid
at the equilibrium of about 16% [25]. Thus, the diminished
accessibility of the pores due to the embedding of PS-DVB
microparticles had a stronger influence on the adsorption of
bilirubin than on the binding of cholic acid, because the pores
remain accessible to the free fraction of the latter metabolite.
The incorporation of 250mg PS-DVB microparticles
into cryogels resulted in a higher decrease in bilirubin and
cholic acid concentrations in comparison to cryogels loaded
with 125mg microparticles. However, when calculating the
amount of metabolites adsorbed per gram of microparticles,
the less densely loaded cryogel composites eliminated biliru-
bin and cholic acid more efficiently, both under static and
dynamic conditions (data not shown).
3.5. Adsorption of Cytokines. Cytokines are mediators of
inflammation and their removal from the blood may be
relevant both in liver failure and as a supportive treatment
option for septic patients [26, 27]. Human plasma was spiked
with TNF-𝛼 and IL-6 to yield concentrations of 535 pg/mL
(TNF-𝛼) and 182 pg/mL (IL-6). Cytokine adsorption was
compared for the parent microparticles and the compos-
ite cryogels containing PS-DVB microparticles (Table 4).
Remarkably, TNF-𝛼, which is a 51 kD homotrimer in its
bioactive form, was removed by plain PS-DVBmicroparticles
to a greater extent than IL-6 (21 kD). This is in contrast to
the hypothesis that adsorption would be more efficient for
smaller solutes due to better accessibility of the pores. This
finding will be further investigated and might eventually be
due to deoligomerization of TNF-𝛼 into its subunits.
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Table 4: Adsorption of TNF-𝛼 and IL-6 on PS-DVBmicroparticles
and composite cryogels after 60min under static conditions (𝑛 = 3).
pmol cytokine adsorbed per g PS-DVB
TNF-𝛼 IL-6
PS-DVB 0.27 ± 0.01 0.18 ± 0.01
PVA + 125mg PS-DVB 0.10 ± 0.03 0.06 ± 0.04
Agarose + 125mg PS-DVB 0.11 ± 0.01 0.11 ± 0.05
Similar to the case of albumin-bound liver toxins, embed-
ding of the PS-DVB microparticles into the cryogels resulted
in decreased cytokine adsorption. This may be explained by
the formation of a hydrophilic polymer layer on the PS-DVB
microparticles during embedment into the cryogels, which
reduces hydrophobic interactions between PS-DVB and the
target cytokines.
3.6. Blood Compatibility. Incubation of PS-DVB microparti-
cles with plasma did not result in an increase of prothrombin
time and activated partial thromboplastin time. Both PT and
aPTT also stayed in the normal range for agarose- and PVA-
based composite cryogels, indicating good blood compati-
bility for PS-DVB microparticles as well as for composite
cryogels (Figure 3).
4. Conclusions
PS-DVB microparticles with defined porosity are efficient
adsorbents for both albumin-bound toxins related to liver
failure and cytokines. In this study, PS-DVB microparticles
were embedded into monolithic cryogels.The resulting com-
posite cryogels did not require filters to support micropar-
ticles and were mechanically stable when perfused with
human plasma at flow rates of 4 to 7mL/min. The composite
cryogels efficiently adsorbed albumin-bound hydrophobic
metabolites related to liver failure (bilirubin, cholic acid)
and cytokines (TNF-𝛼, IL-6). The molecular adsorption
characteristics of PS-DVB microparticles were influenced by
the embedding procedure, and the accessibility of the pores
was diminished due to the formation of a polymer layer on
the surface of the particles.This resulted in a decrease of both
adsorption capacity and rates of adsorption as compared to
the parent microparticles.
The specific adsorption, that is, the amount of target
substance bound per g of adsorbent, was higher for composite
cryogels containing 125mg of particles as compared to the
more densely packed composite cryogels containing 250mg
of particles, indicating that there is an optimal density
of particles within the composite cryogel. The composite
cryogels exhibited good blood compatibility, as global coag-
ulation parameters (prothrombin time and activated partial
thromboplastin time) remained stable after incubation of
the cryogels with plasma. Thus, we conclude that composite
cryogels containing PS-DVB microparticles are suitable as
adsorptionmodules to deplete toxicmetabolites from plasma
for research and production purposes.
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